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SUPPLEMENTATION WITH THREE
DIFFERENT MACULAR CAROTENOID
FORMULATIONS IN PATIENTS
WITH EARLY AGE-RELATED
MACULAR DEGENERATION
SARAH SABOUR-PICKETT, PHD,*†‡ STEPHEN BEATTY, MD, FRCOPHTH,†‡
EITHNE CONNOLLY, BSC,†‡ JAMES LOUGHMAN, PHD,*§ JIM STACK, PHD,† ALAN HOWARD, PHD,¶
RONALD KLEIN, MD, MPH,** BARBARA E. KLEIN, MD, MPH,** STACY M. MEUER, BSC,**
CHELSEA E. MYERS, MSTAT,** KWADWO O. AKUFFO, OD,† JOHN M. NOLAN, PHD†‡
Purpose: To investigate the impact of three different macular carotenoid formulations on
macular pigment optical density and visual performance in subjects with early age-related
macular degeneration.
Methods: Fifty-two subjects were supplemented and followed for 12 months, 17 of them
were in intervention Group 1 (20 mg/day lutein and 2 mg/day zeaxanthin); 21 in Group 2
(10 mg/daymeso-zeaxanthin, 10 mg/day lutein, and 2 mg/day zeaxanthin); and 14 in Group
3 (17 mg/day meso-zeaxanthin, 3 mg/day lutein, and 2 mg/day zeaxanthin). The macular
pigment optical density was measured using customized heterochromatic flicker photom-
etry, and visual function was assessed using corrected distance visual acuity and by letter
contrast sensitivity.
Results: A statistically significant increase in the macular pigment optical density was
observed at all measured eccentricities in Group 2 (P# 0.005) and in Group 3 (P, 0.05, for
all), but only at 1.75° in Group 1 (P = 0.018). Statistically significant (P, 0.05) improvements
in letter contrast sensitivity were seen at all spatial frequencies (except 1.2 cycles per
degree) in Group 3, and at low spatial frequencies in Groups 1 and 2.
Conclusion: Augmentation of the macular pigment optical density across its spatial
profile and enhancements in contrast sensitivity were best achieved after supplementation
with a formulation containing high doses ofmeso-zeaxanthin in combination with lutein and
zeaxanthin.
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The prevalence of age-related macular degeneration(AMD), the leading cause of blind registration in
the developed world,1 is rising because of increasing
longevity.2,3 Although antivascular endothelial growth
factor therapy has resulted in better outcomes for pa-
tients with neovascular AMD,4 this treatment is expen-
sive and cumbersome to the patient and to the health
care provider.
Investigators interested in exploring ways of pre-
venting, delaying the onset, or retarding the pro-
gression of AMD have directed their attention
toward the possible protective role of macular pigment
(MP), a yellow-colored pigment that accumulates
within the inner retinal layers at the macula5 and is
optically undetectable beyond 7° eccentricity.6 Macular
pigment is composed of three carotenoids, lutein (L),
zeaxanthin (Z), and meso-zeaxanthin (MZ).7,8 Macular
pigment has generated interest in recent years because
of its possible protective role for AMD, putatively
attributable to its antioxidant properties and/or its pre-
receptoral filtration of damaging (short-wavelength)
blue light, given that (photo-) oxidative retinal injury
is known to be important in the pathogenesis of this
condition.9,10
Low levels of MP are associated with known risk
factors for AMD, namely, increasing age, a positive
family history of the condition, tobacco use and
obesity, before the onset of disease.11 Furthermore,
1
observational studies have shown that low levels of
carotenoids in the diet12–16 and in the serum13,17–19
are associated with the risk of AMD. Importantly,
MP augmentation has repeatedly been demonstrated
after dietary modification and/or supplementation with
its constituent carotenoids, in subjects with and with-
out AMD.20–26
Although L and Z concentrations in a variety of
foodstuffs have been determined,27,28 the MZ compo-
sition of foodstuffs typical of a western diet has not
been investigated satisfactorily,28 although it has been
identified in certain types of seafood.29 Interestingly,
MZ has been found, albeit in trace amounts, in the
serum of subjects who have not been supplemented
with this carotenoid.30
There is consensus that MP plays an important role
in visual performance. Many cross-sectional studies
have shown a positive association between MP and
measures of visual performance, including visual
acuity, contrast sensitivity (CS), photostress recovery
and glare disability (among others).31–35 It has also
been shown that supplementation with the macular
carotenoids improves parameters of visual function
in patients afflicted with the early form of this condi-
tion.36–38 However, no study has yet investigated the
impact of a formulation containing MZ on visual func-
tion in subjects with early AMD, or on the natural
course of this condition.
Certain properties of MZ render this carotenoid of
particular interest when investigating AMD preven-
tion, or when studying the contribution that MP makes
to visual performance and experience (in subjects with
or without AMD), and these include: MZ is believed
to be generated from L in the primate retina39; MZ
is the dominant carotenoid at the epicenter of the
macula40; MZ seems to be the most powerful antiox-
idant of the macular carotenoids in the presence of the
xanthophyll-binding proteins41; the presence of all
three macular carotenoids is required if MP is to max-
imally exert its antioxidant effects42; the presence of
MZ facilitates a wider range of pre-receptoral blue
light filtration by MP.43,44 Interestingly, an atypical
central dip in the spatial profile of MP, characterized
by the lack of a central peak with a monotonic decline
from the foveal center, is associated with risk for
AMD.45 It is reasonable to hypothesize that such atyp-
ical profiles may be attributable, at least in part, to
a lack of MZ, and a consequential lack of MP at the
site of dominance of this carotenoid (i.e., at the foveal
center). Interestingly, supplementation with a formula-
tion containing MZ has the ability, uniquely, to rebuild
MP centrally and confer a typical central peak to its
spatial profile.30,46
This single-blind, randomized control trial was
designed to compare the effect of three differing
macular carotenoid formulations on MP enhancement,
on visual performance, and on disease progression in
subjects with early AMD.
Methods
Subjects and Study Design
This study was conducted at the Institute of Vision
Research and Institute of Eye Surgery, Waterford,
Ireland. The inclusion criteria were: early AMD (the
presence of drusen and pigmentary changes) in at least
1 eye; corrected distance visual acuity of $6/12 in the
study eye. The exclusion criteria were: a recent history
(within 3 months of baseline visit) of macular carotenoid
supplementation; diabetes mellitus; any visually conse-
quential ocular comorbidity. Ethics approval was
granted by the Waterford Regional Hospital Ethics
Committee, and written informed consent was secured
from each subject. The research was conducted in accor-
dance with the principles of the Declaration of Helsinki.
The Meso-zeaxanthin Ocular Supplementation Trial:
Report 1 (trial registration number: ISRCTN60816411)
is a randomized single-blind clinical trial of oral
supplementation with 1 of 3 different interventions.
Subjects were randomly assigned to one of three
supplementation groups, as follows: Group 1: 20 mg L
and 2 mg Z (Ultra Lutein AU4); Group 2: 10 mg MZ,
10 mg L, and 2 mg Z (Macushield); Group 3:
17 mg MZ, 3 mg L, and 2 mg Z (prepared especially
for this trial by Industrial Organica, Monterrey,
Mexico). Subjects were required to consume one tab-
let daily with a meal. Study visits were carried out at
baseline and at 12 months. A demographic, medical,
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ophthalmic, and lifestyle case history was obtained
for each patient at baseline.
Macular Pigment Optical Density
Each subject’s MP spatial profile was obtained with
the Macular Densitometer, using a methodology that
has been slightly modified from that developed by
Wooten et al.47 A detailed description of this protocol
has been previously described.48,49
Visual Performance
Corrected distance visual acuity was measured for
the study eye monocularly using the Early Treatment
Diabetic Retinopathy Study logMAR chart (Test Chart
2000 PRO; Thomson Software Solutions, Hertford-
shire, England, United Kingdom), with the room lights
on. Contrast sensitivity was also assessed using the
logMAR chart at 5 different spatial frequencies (1.2,
2.4, 6.0, 9.6, and 15.15 cycles per degree). For a given
spatial frequency, subjects were asked to read out the
letters while fixating on the chart at a distance of 6 m.
The letter set was randomized during the test at each
change of contrast. The percentage contrast of letter
optotypes was reduced in 0.15 logCS steps until the
lowest contrast value at which subjects see at least 3
letters was reached. The test is then repeated for the
other spatial frequencies. Each letter has a nominal
logCS value of 0.03. Missed letters at any contrast
level are noted. The resultant logCS value for the
subject at a particular spatial frequency is calculated
by adding any extra letter(s) and/or subtracting missed
letters from best logCS value corresponding to the
lowest percentage contrast.
Morphologic Assessment
Subjects recruited into the study had early AMD. To
establish AMD status, color stereoscopic 30° fundus
photographs were obtained using a Zeiss VisuCam
(Carl Zeiss Meditec AG, Jena, Germany) and were
graded at the Ocular Epidemiology Reading Center
at the University of Wisconsin, Madison, WI, using
a modified version of the Wisconsin Age-Related
Maculopathy Grading System and based on the
11-step AREDS grading scale.50,51 For the purposes
of this study, a change of two or more steps along the
AREDS severity scale was defined as being clinically
meaningful.52
Clinical Pathology Analysis
Clinical pathology analysis was performed by
Biomnis Laboratories (Dublin, Ireland) to test for
changes in renal and liver function, lipid profile,
hematologic profile, and inflammation markers at
baseline and after the 12-month supplementation
period. A detailed description of the protocol has been
previously described by our group.53
Statistical Analysis
Statistical analysis was performed using the soft-
ware package PASW Statistics 18.0 (IBM Corp,
Somers, NY). Power and sample size calculations
were obtained using PASS 2008 (NCSS, LLC, Kaysville,
UT). A priori statistical methodology was not used in this
exploratory study.
Baseline differences between intervention groups
were assessed using analysis of variance and contin-
gency table analysis, as appropriate. Baseline and
12-month visit measures, within each treatment
group, were compared using the paired-samples t-test;
between-group comparisons, using analysis of vari-
ance, would have lacked statistical power because of
the relatively small sample size in this study. The
change in AMD-severity grade between the three
intervention groups was assessed using the Pearson
chi-square test for contingency tables. The 5% level
of significance was used throughout.
For the paired t-test analyses of changes in MP opti-
cal density (MPOD) and CS (reported in Tables 3
and 4), power calculations were based on a “large”
effect size of 0.8 standard deviations (as suggested by
Cohen54), and on the smallest of the group sizes (Group
3, n = 14); this study was not powered to detect smaller
effect sizes, as per Cohen’s definitions.54 With the usual
assumptions (5% level of significance, 2-tailed test), the
power is 0.79 for the Group 3 investigations and higher
than this for the other two groups. For the contingency
table analysis designed to detect changes on the AMD-
severity scale (reported in T5Table 5), we also used
a “large” effect size (W = 0.5 using Cohen’s classifica-
tion) and, in addition, combined some adjacent col-
umns; in this case, the power is 0.78.
Results
Baseline Analysis
Sixty-seven eyes (of 67 subjects) were recruited into
this study. Eight subjects discontinued for personal
reasons, 3 were not available to attend for the 12-
month visit, 2 discontinued for health reasons (deemed
to be unrelated to intervention), 1 had cataract surgery
on the study eye before the 12-month visit, and 1
patient developed neovascular AMD and did not re-
attend, leaving 52 subjects with complete data sets for
the 12-month analyses: 17 in Group 1, 21 in Group 2,
and 14 in Group 3. Baseline demographic, lifestyle,
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anthropometric, and visual data for the remaining 52
subjects are presented
AU5
inT1 Table 1. Of note, there was
no significant difference between the groups in any
baseline data variables (including AMD severity, data
not presented).
Longitudinal Analysis
Values for MPOD at each eccentricity, at baseline,
and 12 months are summarized inT2 Table 2.
Letter CS at baseline and 12 months, for each of the
5 spatial frequencies, is summarized in TableT3 3.
Graphical representations of letter CS at baseline and
at 12 months, for the 3 intervention groups, and for
each spatial frequency, are displayed inF1 Figure 1, A–C.
The proportion of subjects in each intervention
group exhibiting a change in severity scale grade of
two or more, considered clinically meaningful for the
purpose of this study,52 was studied. Seventy-nine per-
cent of subjects exhibited no clinically meaningful
change in AMD severity grade between baseline and
12 months, with 11% exhibiting deterioration and 10%
exhibiting an improvement. There was no statistically
significant difference between treatment groups in
change in the AMD severity scale (P = 0.455, Pearson
chi-square test). The 24- and 36-month data will fur-
ther inform this important analysis.
Clinical pathology analysis results are reported in
Table T44. Of note, 2 variables in Group 1, 2 variables
in Group 2, and 2 variables in Group 3 demonstrated
statistically significant changes from baseline (in both
positive and negative directions). All variables, how-
ever, remained within their respective and normal
reference ranges.
Discussion
The Meso-zeaxanthin Ocular Supplementation Trial
is a randomized single-blind clinical trial that
Table 1. Baseline Demographic, Lifestyle,AU9 Anthropometric, and Visual Data
Entire Group, n (%) Group 1, n (%) Group 2, n (%) Group 3, n (%) Significance
Gender
Male 18 (35) 5 (29) 8 (38) 5 (36) 0.851
Female 34 (65) 12 (71) 13 (62) 9 (64)
Laterality
Right 33 (63) 9 (53) 14 (67) 10 (71) 0.525
Left 19 (37) 8 (47) 7 (33) 4 (29)
Smoking status
Current 4 (8) 2 (12) 2 (10) 0 (0) 0.224
Past 25 (48) 8 (47) 7 (33) 10 (71)
Never 23 (44) 7 (41) 12 (57) 4 (29)
Education
Primary 10 (19) 3 (18) 2 (10) 5 (36) 0.270
Secondary 23 (44) 6 (35) 12 (57) 5 (36)
Third level 19 (37) 8 (47) 7 (33) 4 (28)
Variable Mean ± SD (n = 52) Mean ± SD (n = 17) Mean ± SD (n = 21) Mean ± SD (n = 14)
Age 66 (8) 65 (7) 64 (9) 70 (8) 0.117
BMI, kg/m2 26.1 (5.5) 25.5 (4.1) 27.1 (3.6) 25.2 (8.6) 0.562
CDVA (study eye) 99 (7) 99 (7) 99 (8) 98 (6) 0.868
Letter contrast sensitivity
1.2 cpd 68.3 (46.4) 73.0 (49.1) 61.2 (41.3) 73.2 (52.3) 0.674
2.4 cpd 57.1 (41.2) 59.7 (45.3) 56.8 (40.5) 54.3 (41.4) 0.938
6.0 cpd 25.6 (14.8) 29.0 (14.9) 24.3 (14.0) 23.6 (16.0) 0.530
9.6 cpd 13.7 (8.6) 16.0 (9.1) 12.3 (7.3) 12.9 (9.7) 0.399
15.15 cpd 6.5 (4.9) 7.1 (4.5) 6.2 (4.8) 6.4 (5.7) 0.827
Macular pigment optical density
0.25° eccentricity 0.50 (0.25) 0.50 (0.25) 0.50 (0.24) 0.47 (0.21) 0.925
0.5° eccentricity 0.39 (0.22) 0.38 (0.27) 0.41 (0.22) 0.36 (0.19) 0.797
1.0° eccentricity 0.26 (0.15) 0.27 (0.18) 0.27 (0.13) 0.24 (0.17) 0.851
1.75° eccentricity 0.14 (0.11) 0.16 (0.11) 0.15 (0.11) 0.11 (0.12) 0.554
Diet score* (n = 50)† 18.7 (11.2) 17.3 (10.9) 21.9 (12.7) 16.0 (8.4) 0.267
*A subject’s weekly intake of carotenoid-rich foods was inputted into an L/Z screener to give a carotenoid-based diet score. Values are
weighted for frequency of intake of the food and for bioavailability of L and Z within these foods (the range of scores on the L/Z screener is
0–75).
†Data were not available for 2 subjects.
BMI, body mass index; CDVA, corrected distance visual acuity; cpd, cycles per degree; SD, standard deviation.
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compares the effect of supplementation with three
different macular carotenoid formulations on MPOD,
visual performance, and AMD grade, over a period of
12 months, in subjects with early AMD.
The MPOD was significantly greater at 1 year than
at baseline at all eccentricities for subjects in Groups 2
and 3. Although the observed augmentation in mean
MPOD at 12 months did not reach statistical signif-
icance for subjects supplemented with high doses of L
(Group 1) in the absence of MZ, except at 1.75° eccen-
tricity, it should be noted that the mean increases
observed for this group at other eccentricities were
not dissimilar in magnitude to those observed for
Groups 2 and 3.
The significant rise in MPOD across the spatial
profile when all 3 macular carotenoids (Group 2) are
included in the formulation, or when supplemented
with 17 mg of MZ and small amounts of L and Z
(Group 3), and especially the augmentation of MP
centrally, is neither surprising nor counter-intuitive,
given the known distribution of MP’s individual con-
stituent carotenoids.7 The inclusion of MZ in the for-
mulation is likely to result in augmentation of MP
centrally (demonstrated in Groups 2 and 3 here), as
this is the site of dominance of this carotenoid. In
addition, the inclusion of L in the formulation (as in
Groups 1, 2, and 3) will result in MP augmentation at
the site of that carotenoid’s natural dominance (1.75°),
attested to by augmentation of MP at this locus in the
high L (but no MZ) group (Group 1). It would seem,
therefore, that supplementation with all three macular
carotenoids results in the greatest augmentation of
MPOD across its spatial profile, thereby putatively
affording the greatest protection against AMD. Inter-
estingly, in vitro work has concluded that the antiox-
idant capacity of the macular carotenoids is maximized
when all three macular carotenoids are present.42
It is unsurprising that there were demonstrable
improvements in the CS after augmentation of MP,
especially where such augmentation was demonstrated
centrally, given the consequential enhancement of pre-
receptoral filtration of blue light and attenuation of the
adverse effects of short-wavelength (blue) light scatter.
This is particularly important for subjects with AMD
because CS is an important measure of visual function
in patients afflicted with the condition.55 However, the
inclusion of MZ in the formulation was required to
achieve improvements both at low and high spatial
frequencies.
The observation in this study that supplementation
with high doses of L (in the absence of MZ) resulted in
improved CS at low spatial frequencies only is
consistent with the fact that visual function at low
spatial frequencies will be mediated by slightly
eccentric retinal loci. Of note, concentrations of L
are higher in the peripheral macula, compared with the
foveola.56
Previous studies have investigated the impact of
macular carotenoid supplementation on CS in subjects
with AMD, with most of the studies reporting
improvements in the CS after supplementation (with
L and Z),36,37,57–59 although no study to date has tested
Table 2. Mean (±SD) MPOD at Baseline and 12 Months
Eccentricity
Group 1 Group 2 Group 3
Baseline 12 Months P Baseline 12 Months P Baseline 12 Months P
0.25° 0.50 ± 0.25 0.59 ± 0.30 0.077 0.50 ± 0.25 0.60 ± 0.21 0.005 0.46 ± 0.21 0.59 ± 0.20 0.010
0.5° 0.38 ± 0.27 0.47 ± 0.27 0.055 0.42 ± 0.22 0.50 ± 0.19 0.005 0.36 ± 0.19 0.46 ± 0.21 0.020
1° 0.27 ± 0.18 0.34 ± 0.16 0.083 0.27 ± 0.13 0.34 ± 0.17 0.005 0.24 ± 0.17 0.33 ± 0.16 0.019
1.75° 0.16 ± 0.11 0.21 ± 0.09 0.018 0.14 ± 0.11 0.22 ± 0.12 0.002 0.11 ± 0.12 0.19 ± 0.10 0.006
SD, standard deviation.
Table 3. Mean (±SD) Letter CS Values at Baseline and at 12 Months
cpd
Group 1 Group 2 Group 3
Baseline 12 Months P Baseline 12 Months P Baseline 12 Months P
1.2 73.0 ± 49.1 91.8 ± 48.5 0.021 61.2 ± 41.3 91.9 ± 53.6 0.014 73.2 ± 52.3 92.2 ± 55.0 0.081
2.4 59.7 ± 45.3 86.7 ± 54.2 0.006 56.8 ± 40.5 77.8 ± 51.6 0.008 54.3 ± 41.4 86.2 ± 52.1 0.002
6.0 29.0 ± 14.9 38.1 ± 26.7 0.098 24.3 ± 14.0 30.9 ± 18.8 0.058 23.6 ± 16.0 42.2 ± 25.9 0.002
9.6 16.0 ± 9.1 16.4 ± 9.0 0.939 12.3 ± 7.3 17.5 ± 12.3 0.066 12.9 ± 9.7 20.1 ± 11.9 0.016
15.15 7.1 ± 4.5 7.8 ± 5.5 0.408 6.2 ± 4.8 7.8 ± 6.4 0.189 6.4 ± 5.7 8.7 ± 5.8 0.005
Note: The statistical tests were based on log-transformed data. The P values reported are for the paired t-test (or the corresponding
nonparametric test when the data distribution was non-normal).
cpd, cycles per degree; SD, standard deviation.
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a formulation containing MZ. For example, a study by
Ma et al60 has shown significant increases in CS at low
spatial frequencies after supplementation with either
10 mg L, 20 mg L, or 10 mg L and 10 mg Z (com-
bined), in subjects with early AMD, over a 48-week
study period. These findings are in agreement with
those reported in this study, which found demonstrable
improvements in CS at high spatial frequencies, but
only among subjects who were supplemented with
a formulation containing MZ, and not among subjects
supplementing with high doses of L alone.
This study has shown that, from a morphologic
perspective, AMD remains stable for at least 12
months after supplementation with the macular car-
otenoids. However, the findings presented here must
be interpreted with full appreciation of the study’s
principal weaknesses, and these include the small
numbers of subjects involved, the study’s short dura-
tion, and the absence of a placebo group. For the pur-
poses of discussion, it is reasonable to compare our
findings with the placebo group in the recently pub-
lished Carotenoids in Age-Related MAculopathy
study, which was a randomized, double-blind, pla-
cebo-controlled clinical trial of L (12 mg) and Z
(0.6 mg) supplementation with co-antioxidants versus
placebo in patients with early AMD.61 The study pop-
ulation of the Carotenoids in Age-Related MAculop-
athy study is comparable with that of our study, in
inclusion and exclusion criteria, methodology of
AMD grading, and demographic and geographic con-
siderations. However, in the Carotenoids in Age-
Related MAculopathy study, at 12 months, 47.4% of
eyes in the placebo arm (108 of 228 eyes) exhibited an
increase of least one grade (progression) along the
AMD severity scale (data on file). Interestingly, in this
study, only 27% of subjects (all of whom were sup-
plementing with the macular carotenoids) showed pro-
gression by one or more steps at 12 months. Of course,
a historical comparison such as this one should be
interpreted with full appreciation of the fact that the
natural course of AMD, particularly over a 12-month
period, may not be clinically significant.
No discussion of our findings would be complete
without reference to the recently published AREDS2
reports,62,63 where analysis of secondary outcomes
indicated a benefit of supplementation with L and Z,
in terms of AMD progression and preservation of
vision, especially in subjects with low dietary intake
of those two carotenoids. Given that only two of the
three macular carotenoids were used in AREDS2, our
findings are rendered all the more clinically meaning-
ful, if not somewhat provocative.
Of note, AREDS, published in 2001,64 was criti-
cized for non-inclusion of L and Z, and that omission
Fig 1. Letter CS at baseline and at 12 months, for Groups 1 (A), 2 (B),
and 3 (C).AU8
6 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES ! 2014 ! VOLUME 0 ! NUMBER 0
Table 4. Clinical Pathology Variables Following Supplementation With the Macular Carotenoids Assessed at Baseline and
at 12 months for Each of the Three Intervention Groups
Pathology Variable Function of Test Reference Range (Unit)*
Group 1 (n = 9)†
Baseline 12 Months P
Sodium Renal profile 135–145 (mmol/L) 139 ± 3 138 ± 3 0.312
Potassium Renal profile 3.3–5.3 (mmol/L) 4.6 ± 0.3 4.7 ± 0.2 0.366
Chloride Renal profile 98–107 (mmol/L) 104 ± 2 106 ± 2 0.073
Urea Renal profile 2.5–7.7 (mmol/L) 7.2 ± 2.4 6.5 ± 1.4 0.174
Creatinine Renal profile 40–90 (mmol/L) 81 ± 13 74 ± 10 0.086
Total protein Liver profile 64–83 (g/L) 69 ± 3 68 ± 3 0.499
Albumin Liver profile 37–52 (g/L) 41 ± 2 40 ± 3 0.444
Globulins Liver profile 21–36 (g/L) 28 ± 4 28 ± 3 1.000
Total bilirubin Liver profile 3.4–21.0 (mmol/L) 6.2 ± 2.0 7.8 ± 2.2 0.050
AAT Liver profile 0–55 IU/L 23 ± 8 21 ± 8 0.426
ASA Liver profile 5–36 IU/L 24 ± 3 24 ± 4 0.782
Alkaline phosphate Liver profile 40–150 IU/L 79 ± 27 87 ± 31 0.013
GGT Liver profile 9–36 IU/L 39 ± 40 40 ± 41 0.668
Cholesterol total Lipid profile ,5.0 (mmol/L) 5.2 ± 1.0 5.2 ± 1.1 0.708
Triglycerides Lipid profile 0.60–1.70 (mmol/L) 1.47 ± 0.61 1.34 ± 0.66 0.185
HDL Lipid profile 1.00–1.55 (mmol/L) 1.51 ± 0.37 1.43 ± 0.31 0.063
Direct LDL Lipid profile ,3.0 (mmol/L) 3.1 ± 1.0 3.2 ± 1.0 0.419
Calcium Bone profile 2.10–2.60 (mmol/L) 2.31 ± 0.10 2.32 ± 0.14 0.661
Phosphate Bone profile 0.80–1.56 (mmol/L) 1.13 ± 0.17 1.20 ± 0.24 0.292
Magnesium Bone profile 0.65–1.10 (mmol/L) 0.99 ± 0.05 0.94 ± 0.09 0.159
Uric Acid Bone profile 155–394 (mmol/L) 290 ± 54 280 ± 62 0.579
Glucose Bone profile 3.1–6.1 (mmol/L) 5.3 ± 0.7 5.3 ± 1.2 0.910
HSRP Inflammation
marker
,5.0 (mg/L) 1.2 ± 0.5 1.6 ± 1.0 0.097
Full blood count
Leukocyte count Hematology 3.88–10.49 (10e9/L) 6.54 ± 2.00 5.88 ± 1.03 0.331
Erythrocyte count Hematology 3.73–5.02 (10e12/L) 4.51 ± 0.42 4.36 ± 0.33 0.367
Hemoglobin Hematology 11.3–15.2 (g/dL) 13.6 ± 1.1 13.6 ± 0.9 0.622
Hematocrit Hematology 0.323–0.462 (L/L) 0.407 ± 0.032 0.405 ± 0.020 0.769
MCV Hematology 83.1–99.1 (fL) 90.5 ± 3.1 93.1 ± 5.1 0.222
MCH Hematology 28.3–33.9 (pg) 30.1 ± 1.2 31.3 ± 1.8 0.134
MCHC Hematology 32.1–36.6 (g/dL) 33.3 ± 1.0 33.6 ± 0.8 0.357
Platelets Hematology 164–382 (10e9/L) 332 ± 249 249 ± 123 0.196
Differential white cell count
Neutrophils Hematology 1.91–7.16 (10e9/L) 3.80 ± 1.27 3.44 ± 0.82 0.423
Lymphocytes Hematology 1.01–3.13 (10e9/L) 1.82 ± 0.54 1.66 ± 0.39 0.309
Monocytes Hematology 0.19–0.68 (10e9/L) 0.47 ± 0.18 0.40 ± 0.13 0.322
Eosinophils Hematology 0.05–0.51 (10e9/L) 0.22 ± 0.05 0.18 ± 0.06 0.195
Basophils Hematology 0.02–0.15 (10e9/L) 0.05 ± 0.03 0.05 ± 0.02 0.505
Large unstained cells Hematology 0.00–0.30 (10e9/L) 0.17 ± 0.07 0.14 ± 0.03 0.222
Pathology Variable
Group 2 (n = 20)† Group 3 (n = 12)†
Baseline 12 Months P Baseline 12 Months P
Sodium 141 ± 3 138 ± 2 0.001 136 ± 3 137 ± 4 0.371
Potassium 4.6 ± 0.4 4.7 ± 0.4 0.475 4.7 ± 0.3 4.8 ± 0.2 0.709
Chloride 104 ± 3 104 ± 3 0.922 103 ± 4 103 ± 4 0.612
Urea 6.1 ± 1.1 6.6 ± 1.5 0.073 6.7 ± 1.5 6.0 ± 1.7 0.053
Creatinine 78 ± 14 77 ± 15 0.299 76 ± 19 75 ± 17 0.681
Total protein 71 ± 4 70 ± 3 0.415 70 ± 5 70 ± 5 0.558
Albumin 43 ± 2 42 ± 2 0.134 41 ± 2 42 ± 2 0.410
Globulins 28 ± 4 29 ± 3 0.737 29 ± 5 28 ± 4 0.272
Total bilirubin 9.1 ± 4.7 9.9 ± 5.3 0.293 8.0 ± 3.6 10.1 ± 4.0 AU12AU12 0.001
AAT 22 ± 6 22 ± 6 0.752 19 ± 3 20 ± 5 0.279
ASA 22 ± 4 22 ± 4 0.903 21 ± 3 22 ± 4 0.083
Alkaline phosphate 78 ± 20 79 ± 20 0.501 76 ± 11 82 ± 17 0.114
GGT 27 ± 11 28 ± 14 0.395 27 ± 16 32 ± 23 0.075
(continued on next page)
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prompted AREDS2. Our findings, however, suggest
that the exclusion of MZ in AREDS2 represents
a potential shortcoming of that study, especially given
that MP was measured in less than 2% of AREDS2
patients. Certainly, the opportunity to demonstrate fur-
ther visual benefit by inclusion of all three of MP’s
constituent carotenoids was missed, and warrants fur-
ther study. In this vein, a head-to-head randomized,
double-blind, controlled trial of the AREDS2 formula
versus the AREDS2 formula fortified with MZ is cur-
rently underway.65
Conclusion
Macular pigment can be augmented, and CS
enhanced, in subjects with early AMD who receive
supplemental macular carotenoids. A formulation
containing all three macular carotenoids (L, Z, and
MZ) may offer advantages over a formulation that
does not contain MZ, in terms of improvements in CS
and MP augmentation across its spatial profile, the
latter putatively affording greater protection against
(photo-) oxidative injury. The results of this study
Table 4. (Continued )
Pathology Variable
Group 2 (n = 20)† Group 3 (n = 12)†
Baseline 12 Months P Baseline 12 Months P
Cholesterol total 4.7 ± 1.3 4.5 ± 0.9 0.231 4.8 ± 1.0 4.8 ± 0.9 1.000
Triglycerides 1.44 ± 0.49 1.39 ± 0.60 0.700 1.51 ± 1.31 1.29 ± 0.82 0.236
HDL 1.31 ± 0.33 1.24 ± 0.28 0.044 1.46 ± 0.47 1.46 ± 0.51 0.942
Direct LDL 2.8 ± 1.1 2.7 ± 0.8 0.317 2.8 ± 0.9 2.7 ± 0.9 0.671
Calcium 2.35 ± 0.07 2.35 ± 0.07 0.825 2.31 ± 0.06 2.40 ± 0.11 0.005
Phosphate 1.17 ± 0.17 1.19 ± 0.19 0.672 1.07 ± 0.25 1.10 ± 0.21 0.414
Magnesium 0.97 ± 0.08 0.98 ± 0.06 0.573 0.93 ± 0.12 0.94 ± 0.08 0.599
Uric Acid 315 ± 65 312 ± 66 0.724 305 ± 65 322 ± 89 0.260
Glucose 5.0 ± 0.6 5.0 ± 0.7 0.867 5.0 ± 0.9 5.1 ± 0.7 0.273
HSRP 2.2 ± 2.4 2.3 ± 2.1 0.864 4.0 ± 5.1 4.3 ± 6.7 0.728
Full blood count
Leukocyte count 6.74 ± 1.53 6.81 ± 1.78 0.830 6.13 ± 1.56 5.95 ± 1.10 0.661
Erythrocyte count 4.50 ± 0.41 4.47 ± 0.39 0.377 4.44 ± 0.45 4.46 ± 0.45 0.858
Hemoglobin 13.7 ± 1.1 13.7 ± 1.2 0.596 13.6 ± 1.2 13.6 ± 1.1 0.969
Hematocrit 0.413 ± 0.031 0.413 ± 0.031 0.939 0.409 ± 0.031 0.412 ± 0.031 0.779
MCV 92.0 ± 4.0 92.6 ± 4.0 0.414 92.4 ± 3.7 92.6 ± 3.7 0.778
MCH 30.4 ± 1.3 30.8 ± 1.2 0.167 30.7 ± 1.2 30.5 ± 1.4 0.632
MCHC 33.1 ± 0.8 33.3 ± 1.2 0.523 33.2 ± 1.1 33.0 ± 1.0 0.468
Platelets 258 ± 88 250 ± 118 0.527 244 ± 46 254 ± 61 0.369
Neutrophils 4.09 ± 1.20 4.23 ± 1.38 0.580 3.92 ± 1.23 3.84 ± 1.21 0.809
Lymphocytes 1.81 ± 0.43 1.70 ± 0.42 0.128 1.42 ± 0.36 1.38 ± 0.39 0.704
Monocytes 0.43 ± 0.11 0.45 ± 0.16 0.495 0.41 ± 0.12 0.35 ± 0.09 0.132
Eosinophils 0.18 ± 0.09 0.23 ± 0.13 0.055 0.17 ± 0.10 0.17 ± 0.08 1.000
Basophils 0.05 ± 0.02 0.07 ± 0.04 0.063 0.04 ± 0.02 0.06 ± 0.03 0.042
Large unstained cells 0.18 ± 0.07 0.16 ± 0.05 0.122 0.16 ± 0.05 0.14 ± 0.02 0.177
*The normative reference ranges for this study were obtained from the insert kits for the instrumentation used by Biomnis Laboratories.
Exceptions were the reference ranges for lipids (HDL, LDL, total cholesterol, and triglycerides), which were obtained from the European
Guidelines on Cardiovascular Disease Prevention, (69) and for glucose, which were obtained from the World Health Organization (70).AU10
†Total n 6¼ 52 because data on pathology analysis was not available for all subjects at both baseline and 12 months.AU11
AAT, alanine aminotransferase; ASA, aspartate aminotransferase; GGT, gamma glutamyl transpeptidase; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; HSCP, high sensitive reactive protein; MCH, mean corpuscular hemoglobin; MCHC, mean
corpuscular hemoglobin concentration; MCV, mean corpuscular volume.
Table 5. Change in AMD Grade (11-Step Scale) Between Baseline and 12 Months
Group n −2 (%) −1 (%) 0 (%) +1 (%) +2 (%) +3 (%) Significance
1 17 1 (5.9) 1 (5.9) 10 (58.8) 3 (17.6) 1 (5.9) 1 (5.9) 0.455
2 21 3 (14.3) 2 (9.5) 11 (52.4) 3 (14.3) 2 (9.5) 0
3 14 2 (14.3) 5 (35.7) 4 (28.6) 2 (14.3) 1 (7.1) 0
Total 52 (100%) 6 (11.5) 8 (15.4) 25 (48.1) 8 (15.4) 4 (7.7) 1 (1.9)
Negative value, disease progression; positive value, disease regression; 0, no change in grade.
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should inform and prompt a well-designed, controlled
clinical trial of supplementation with L, Z, and MZ in
subjects with AMD, where outcome measures should
include visual function and disease progression.
Key words: lutein, zeaxanthin, meso-zeaxanthin,
age-related macular degeneration, visual performance.
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